Objectives: The benefits of combined chelation therapy with daily deferiprone (DFP) and
subcutaneous desferrioxamine (DFO) have been widely reported in literature. We …

BACKGROUND AND OBJECTIVES: Effective and convenient iron chelation remains one of
the main targets of clinical management of thalassemia major. The combined treatment with …

Abstract Background and Objectives The aim of this prospective, randomized, 1-year study
was to compare the efficacy and safety of oral deferiprone (DFP) with those of combinations …

The availability of three iron chelators improved the scenario of chelation therapy for
transfusion-dependent thalassemia (TDT) patients, allowing tailoring of drugs according to …

Introduction: The best and effective iron chelation remain one of the major strategy in clinical
management of thalassemia major patients. The purpose of this study was to evaluate the …

Several clinical studies have shown that the combination of deferiprone (DFP) with
desferrioxamine (DFO) is efficacious with regard to decrease in serum ferritin (SF), reduction …

Iron overload is the primary cause of mortality and morbidity in thalassemia major despite
advances in chelation therapy. We performed a pilot clinical trial to evaluate the safety and …

Patients with thalassemia major requiring regular blood transfusions accumulate iron that is
toxic to the heart, liver, and endocrine systems. The following prospective, randomized trial …

Introduction: Iron‐chelating therapy with deferoxamine in patients with thalassemia major
has dramatically improved the prognosis of this disease. However, the limitations of this …

Methods This prospective randomized study included 60 patients with transfusion-
dependent β-TM during the period from September 2014 to September 2015. Their ages …